Table 1.
Relationship between Non-overlapping primary molecular cytogenetic abnormalities and myeloma defining event at diagnosis.
| FISH abnormality | Overall (n=484) No. of patients (%) |
Bone disease variant (n=168) No. of patients (%)* |
Renal Failure variant (n=37) No. of patients (%)* |
Anemia variant (n=71) No. of patients (%)* |
Mixed variant (n=208) No. of patients (%)* |
|---|---|---|---|---|---|
| Trisomy (ies) without IgH abnormality | 201 (42%) | 70 (41.7%) | 7 (18.9%) | 32 (45.1%) | 92 (44.2%) |
| IgH abnormality without trisomy (ies) | 146 (30%) | 42 (25.0%) | 19 (51.4%) | 20 (28.2%) | 65 (31.3%) |
| t(11;14) | 74 (15%) | 26 (15.5%) | 6 (16.2%) | 9 (12.7%) | 33 (15.9%) |
| t(4;14) | 28 (6%) | 6 (3.6%) | 2 (5.4%) | 5 (7.0%) | 15 (7.2%) |
| t(14;16) | 19 (4%) | 2 (1.2%) | 5 (13.5%) | 3 (4.2%) | 9 (4.3%) |
| t(14;20) | 1 (<1%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (0.5%) |
| Unknown partner/deletion of IgH region | 24 (5%) | 8 (4.8%) | 6 (16.2) | 3 (4.2%) | 7 (3.4%) |
| IgH abnormality with Trisomy (ies) | 74 (15%) | 26 (15.5%) | 4 (10.8) | 13 (18.3%) | 31 (14.9%) |
| t(11;14) | 12 (3%) | 4 (2.4%) | 0 (0.0%) | 3 (4.2%) | 5 (2.4%) |
| t(4;14) | 19 (4%) | 6 (3.6%) | 1 (2.7%) | 6 (8.5%) | 6 (2.9%) |
| t(14;16) | 5 (1%) | 1 (0.6%) | 1 (2.7%) | 1 (1.4%) | 2 (1.0%) |
| t(6;14) | 3 (<1%) | 1 (0.6%) | 0 (0.0%) | 1 (1.4%) | 1 (.5%) |
| Unknown partner/deletion of IgH region | 35 (7%) | 14 (8.3%) | 2 (5.4%) | 2 (2.8%) | 17 (8.2%) |
| Monosomy 14 in absence of IgH translocations or trisomy (ies) | 22 (4.5%) | 12 (7.1%) | 3 (8.1%) | 2 (2.8%) | 5 (2.4%) |
| Other cytogenetic abnormalities in absence of IgH translocations or trisomy (ies) or monosomy 14* | 26 (5.5%) | 9 (5.4%) | 1 (2.7%) | 3 (4.2%) | 13 (6.3%) |
| Normal | 15 (3%) | 9 (5.4%) | 3 (8.1%) | 1 (1.4%) | 2 (1.0%) |
*
Number and proportion represents the breakdown of patients presenting with each MDE according to cytogenetic subtype